H
Hareth Nahi
Researcher at Karolinska University Hospital
Publications - 208
Citations - 9872
Hareth Nahi is an academic researcher from Karolinska University Hospital. The author has contributed to research in topics: Multiple myeloma & Daratumumab. The author has an hindex of 36, co-authored 182 publications receiving 7906 citations. Previous affiliations of Hareth Nahi include Karolinska Institutet.
Papers
More filters
Journal ArticleDOI
Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma
Bhairavi Swaminathan,Guðmar Thorleifsson,Magnus Jöud,Mina Ali,Ellinor Johnsson,Ram Ajore,Patrick Sulem,Britt-Marie Halvarsson,Guðmundur I Eyjólfsson,Vilhelmina Haraldsdottir,Christina M. Hultman,Erik Ingelsson,Sigurður Yngvi Kristinsson,Anna K. Kähler,Stig Lenhoff,Gisli Masson,Ulf-Henrik Mellqvist,Robert Månsson,Sven Nelander,Isleifur Olafsson,Ólöf Sigurðardóttir,Hlif Steingrimsdottir,Annette Juul Vangsted,Ulla Vogel,Anders Waage,Hareth Nahi,Daniel F. Gudbjartsson,Thorunn Rafnar,Ingemar Turesson,Urban Gullberg,Kari Stefansson,Markus Hansson,Unnur Thorsteinsdottir,Björn Nilsson,Björn Nilsson +34 more
TL;DR: A genome-wide association study in the Nordic region identifying a novel MM risk locus at ELL2 that encodes a stoichiometrically limiting component of the super-elongation complex that drives secretory-specific immunoglobulin mRNA production and transcriptional regulation in plasma cells is reported.
Journal ArticleDOI
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos,Albert Oriol,Hareth Nahi,Jesús F. San-Miguel,Nizar J. Bahlis,Saad Z. Usmani,Neil Rabin,Robert Z. Orlowski,Mieczysław Komarnicki,Kenshi Suzuki,Torben Plesner,Sung-Soo Yoon,Dina Ben Yehuda,Paul G. Richardson,Hartmut Goldschmidt,Hartmut Goldschmidt,Donna E. Reece,Steen Lisby,Nushmia Z. Khokhar,Lisa O'Rourke,Christopher Chiu,Xiang Qin,Mary E. Guckert,Tahamtan Ahmadi,Philippe Moreau +24 more
TL;DR: The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma.
Journal ArticleDOI
Targeting CD38 with daratumumab monotherapy in multiple myeloma
Henk M. Lokhorst,Torben Plesner,Jacob P. Laubach,Hareth Nahi,Peter Gimsing,Markus Hansson,Monique C. Minnema,Ulrik Lassen,Ulrik Lassen,Jakub Krejcik,Antonio Palumbo,Niels W.C.J. van de Donk,Tahamtan Ahmadi,Imran Khan,Clarissa M. Uhlar,Jianping Wang,A. Kate Sasser,Nedjad Losic,Steen Lisby,Linda Basse,Nikolai Constantin Brun,Paul G. Richardson +21 more
TL;DR: Daratumumab monotherapy had a favorable safety profile and encouraging efficacy in patients with heavily pretreated and refractory myeloma, and no maximum tolerated dose was identified in part 1.
Journal ArticleDOI
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Jesús F. San-Miguel,V. Hungria,Sung-Soo Yoon,Meral Beksac,Meletios A. Dimopoulos,Ashraf Elghandour,Wiesław Wiktor Jędrzejczak,Andreas Günther,Thanyaphong Na Nakorn,Noppadol Siritanaratkul,Paolo Corradini,Suporn Chuncharunee,Je-Jung Lee,Robert L. Schlossman,Tatiana Shelekhova,Kwee Yong,Daryl Tan,Tontanai Numbenjapon,Jamie Cavenagh,Jian Hou,Richard Leblanc,Hareth Nahi,Lugui Qiu,Hans Salwender,Stefano Pulini,Philippe Moreau,Krzysztof Warzocha,Darrell White,Joan Bladé,Wenming Chen,Javier de la Rubia,Peter Gimsing,Sagar Lonial,Jonathan L. Kaufman,Enrique M. Ocio,Ljupco Veskovski,Sang Kyun Sohn,Ming Chung Wang,Jae Hoon Lee,Hermann Einsele,Monika Sopala,Claudia Corrado,Bourras Rezki Bengoudifa,Florence Binlich,Paul G. Richardson +44 more
TL;DR: Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical studies has synergistic anti-myeloma activity when combined with bortezomib and dexamethasone and the proportion of patients achieving an overall response did not differ between treatment groups.
Journal ArticleDOI
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Thierry Facon,Shaji Kumar,Torben Plesner,Robert Z. Orlowski,Philippe Moreau,Nizar J. Bahlis,Supratik Basu,Hareth Nahi,Cyrille Hulin,Hang Quach,Hartmut Goldschmidt,Michael O'Dwyer,Aurore Perrot,Christopher P. Venner,Katja Weisel,Joseph R. Mace,Noopur Raje,Michel Attal,Mourad Tiab,Margaret Macro,Laurent Frenzel,Xavier Leleu,Tahamtan Ahmadi,Christopher Chiu,Jianping Wang,Rian Van Rampelbergh,Clarissa M. Uhlar,Rachel Kobos,Ming Qi,Saad Z. Usmani,Maia Trial Investigators +30 more
TL;DR: Among patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation, the risk of disease progression or death was significantly lower among those who received daratumumab plus lenalidomide and dexamethasone than among thosewho received lenalidmide and Dexameth asone alone.